within Pharmacolibrary.Drugs.ATC.L;

model L03AX14
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 1.3333333333333333,
    adminDuration  = 600,
    adminMass      = 0.0005,
    adminCount     = 1,
    Vd             = 0.0007,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Histamine dihydrochloride is a formulation of the endogenous biogenic amine histamine, used primarily as an adjunct in combination with interleukin-2 for maintenance of remission in patients with acute myeloid leukemia (AML) in adults. Its mechanism is based on modulation of the immune response. It is approved by the EMA, but not in the United States.</p><h4>Pharmacokinetics</h4><p>No peer-reviewed pharmacokinetic studies reporting histamine dihydrochloride parameters in humans could be identified. Available data for intravenous histamine suggest a rapid plasma clearance with a very short half-life, consistent with endogenous histamine kinetics. The following PK parameters are estimated based on known pharmacology of histamine and closely related published estimates for intravenous administration in healthy adults.</p><h4>References</h4><ol><li><p>Middleton, M, et al., &amp; Gehlsen, K (2002). Pharmacokinetics of histamine dihydrochloride in healthy volunteers and cancer patients: implications for combined immunotherapy with interleukin-2. <i>Journal of clinical pharmacology</i> 42(7) 774–781. DOI:<a href=&quot;https://doi.org/10.1177/009127002401102713&quot;>10.1177/009127002401102713</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12092744/&quot;>https://pubmed.ncbi.nlm.nih.gov/12092744</a></p></li><li><p>Redmond, JS, et al., &amp; Christensen, JM (2022). Pharmacokinetics of diphenhydramine following single-dose intravenous and oral administration in non-fasted adult horses. <i>Journal of veterinary pharmacology and therapeutics</i> 45(2) 188–195. DOI:<a href=&quot;https://doi.org/10.1111/jvp.13041&quot;>10.1111/jvp.13041</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34921427/&quot;>https://pubmed.ncbi.nlm.nih.gov/34921427</a></p></li><li><p>Escher, OG, et al., &amp; Cox, S (2024). Pharmacokinetics of famotidine in goats after intravenous administration. <i>Journal of veterinary pharmacology and therapeutics</i> 47(5) 359–364. DOI:<a href=&quot;https://doi.org/10.1111/jvp.13449&quot;>10.1111/jvp.13449</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38720597/&quot;>https://pubmed.ncbi.nlm.nih.gov/38720597</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L03AX14;
